Overview


According to FutureWise analysis the market for bulbospinal muscular atrophy drugs is expected to register a CAGR of 12.90% from 2024-2032.

Bulbospinal muscle atrophy (also known as Kennedy's Disease) is a condition in which a bulb-like structure develops in the lower brain. This contains nerve cells that control muscles in the mouth, throat, and face. This condition is caused by the loss of nerve cells in both the brain stem (brain stem) and the spinal cord. It causes a stoppage in messages between the brain and muscles to allow for movement. Patients with this condition have trouble speaking, standing, walking, and controlling their head movements. Patients can also have difficulty swallowing or breathing. This condition is mainly seen in men. It does not affect women. The low testosterone levels in the body protect them, which accounts for the sex-limited inheritance of the disorder. This condition is caused by mutations in the Androgen Receptor gene. It is inherited as an x-linked recessive. Research continues, but as with many genetic disorders, there is no cure. Due to its endocrine manifestations, SBMA patients may experience partial symptoms of Androgen Insensitivity Syndrome. (AIS), along with neuromuscular degeneration.

SBMA can also be linked to neurodegenerative diseases such as Huntington's Disease. The age at which the disease begins is between 30-60 years old. Initial symptoms include fatigue, muscle twitching and muscle cramps. As the disease progresses, patients also experience weakness and wasting in their limbs and bulbar muscles. This manifests as dysarthria and dysphonia, hanging mouth, tongue wasting and chewing difficulties, and impaired mobility. The intellectual decline is very rare. Some patients may not be able to swallow or breathe in the final stages of the disease. Other non-neurological signs include gynecomastia and hypogonadism, which can lead to infertility or impotence, and in rare cases dupuytren’s contracture, or even groin hernia. Bulbar muscles are supplied by motor nerves in the brain stem that controls swallowing, speech and other functions. Lower motor neurons are the ones in the brainstem or spinal cord that supply muscles directly. Loss of lower motor neurons leads to weakness or wasting of the muscle. If the bottom of the foot gets scraped, the toes will bend down. An abnormal response would be for the toes to move upwards.

This indicates a problem with the higher-level (upper), motor neurons. Early symptoms include weakness in the tongue and mouth muscles, fasciculations and slowly increasing weakness in the limb muscles. Although the disease progresses slowly, neuromuscular management can be very supportive. However, it can eventually cause severe disability. Medical history, clinical examination, elevated creatine, testosterone, progesterone and follicle-stimulating hormone are all used to diagnose the condition. Other factors include reduced nerve conduction speeds or decreased nerve action potential amplitude, acute and chronic denervation, electromyography, documentation of the mutation, and re-innervation. Hereditary spastic paraplegia, spinocerebellar and other motor neuron diseases are possible diagnoses (see these terms), myopathies, neuropathies as well as lead or aluminum poisoning and cervical spondylosis.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Bulbospinal Muscular Atrophy Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Bulbospinal Muscular Atrophy Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Noavrtis AG
  • Roche
  • Boehringerlngelheim
  • Leadiant biosciences Inc
  • Abbott
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • AstaZeneca
  • Catalyst Pharma
  • PTC Therapeutics
  • Natera

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • 5a-Reductase Inhibitors (5-ARIs)
  • Gonadotropin-releasing Hormone (GnRH) Agonists
  • Others

By Drugs

  • Leuproprelin
  • Dutasteride
  • Others

By Therapy

  • Physical Therapy
  • Occupaional Therpay
  • Speech Therapy

By Treatment

  • Medication
  • Supportive Care and Surgery

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End-User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Bulbospinal Muscular Atrophy Drugs Market By Drug Class, By Drugs, By Therapy, By Treatment, By Route of Administration, By Distribution Channel, By End-User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Bulbospinal Muscular Atrophy Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Bulbospinal Muscular Atrophy Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Bulbospinal Muscular Atrophy Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Bulbospinal Muscular Atrophy Drugs Market, By Drug Class Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. 5a-Reductase Inhibitors (5-ARIs)
        2. Gonadotropin-releasing Hormone (GnRH) Agonists
        3. Others

  • 8.   Bulbospinal Muscular Atrophy Drugs Market, By Drugs Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Leuproprelin
        2. Dutasteride
        3. Others

  • 9.   Bulbospinal Muscular Atrophy Drugs Market, By Therapy Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Physical Therapy
        2. Occupaional Therpay
        3. Speech Therapy

  • 10.   Bulbospinal Muscular Atrophy Drugs Market, By Treatment Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Medication
        2. Supportive Care and Surgery

  • 11.   Bulbospinal Muscular Atrophy Drugs Market, By Route of Administration Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Oral
        2. Parenteral

  • 12.   Bulbospinal Muscular Atrophy Drugs Market, By Distribution Channel Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy

  • 13.   Bulbospinal Muscular Atrophy Drugs Market, By End-User Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others

  • 14.   North America Bulbospinal Muscular Atrophy Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 15.   Latin America Bulbospinal Muscular Atrophy Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 16.   Europe Bulbospinal Muscular Atrophy Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 17.   Asia Pacific Bulbospinal Muscular Atrophy Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 18.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 19.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 20.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Noavrtis AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Roche
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Boehringerlngelheim
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Leadiant biosciences Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Abbott
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novo Nordisk A/S
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Takeda Pharmaceutical Company Limited
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. AstaZeneca
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Catalyst Pharma
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. PTC Therapeutics
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Natera
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview

  • 21.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 22.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients